Bioarctic Ab Class B · OMXSTO:BIOA_B
Bioarctic Ab Class B — Q1 2022 Earnings Presentation
18 slides from Bioarctic Ab Class B's earnings presentation, Apr 28, 2022
Slide 1: Q1 Report January-March 2022
BIOARCTIC AB (PUBL) NASDAQ STOCKHOLM: BIOA B Q1 Report January-March 2022 Stockholm, April 28, 2022 Gunilla Osswald, PhD, CEO Jan Mattsson, CFO BioArctic AB
Slide 2: Disclaimer
Disclaimer • This presentation has been prepared and produced by BioArctic AB (publ) (“BioArctic”) solely for the benefit of investment analysis of BioArctic and may not be used for any other purpose. Unless otherwise stated, BioArctic is the source for all data contained in this presentation. Such
Slide 3: BioArctic – a unique Swedish biopharma company
BioArctic – a unique Swedish biopharma company Improving life for patients with central nervous system disorders High unmet need for disease-modifying treatments for Alzheimer’s and Parkinson’s diseases creates large commercial opportunity World-class research and development driven organization wit
Slide 4: Attractive and well-balanced project portfolio
Attractive and well-balanced project portfolio Project Partner Discovery Preclinical Phase 1 Phase 2 Phase 3 ALZHEIMER’S DISEASE Lecanemab (BAN2401) (Clarity AD) Eisai1 Early Alzheimer’s disease3 Lecanemab (BAN2401) (AHEAD 3-45) Eisai1 Preclinical (asymptomatic) Alzheimer’s disease4 BAN2401 back-up
Slide 5: Partnership model to de-risk clinical development and optimize commercialization
Partnership model to de-risk clinical development and optimize commercialization opportunity Alzheimer’s disease Parkinson’s disease Partner track record Approved product for symptoms associated with Parkinson’s disease Discovered and developed Used to treat confusion world’s best-selling medicine W
Slide 6: Q1 highlights
Q1 highlights Alzheimer’s disease – Lecanemab • Eisai initiates submission of application data of lecanemab under the prior assessment consultation system in Japan, with the aim of an earlier regulatory approval • Data presented at AD/PD congress in March continue to further strengthen and different
Slide 7: New data presented at AD/PD 2022 continues to strengthen lecanemab
New data presented at AD/PD 2022 continues to strengthen lecanemab Robust effect on blood biomarkers in Phase 2b (Aβ 42/40 and p-tau 181) “the AD/PD conference 2022 showcases the great achievements being done within the field and there is excitement towards the key results coming later this year” Bl
Slide 8: Events after the quarter
Events after the quarter Parkinson’s disease – AbbVie • AbbVie took a strategic business decision to end its collaboration with BioArctic on the alpha-synuclein portfolio, including ABBV-0805. BioArctic will now, in accordance with the license agreement, take back the project and evaluate the best w
Slide 9: Disease modeling suggests lecanemab could delay progression to Alzheimer's dementia
Disease modeling suggests that lecanemab could delay progression to Alzheimer´s dementia by several years Simulated mean time advancing to mild, moderate, and severe Alzheimer’s disease (AD) dementia was longer for patients in the lecanemab-treated group than for patients in the standard of care gro
Slide 10: Lecanemab – broad late-stage clinical program
Lecanemab – broad late-stage clinical program Disease stage Early AD Pre-clinical AD MCI Mild AD Moderate AD Severe AD FDA guideline Stage 1 Stage 2 Stage 3 Stage 4 Stage 5 Stage 6 Clarity AD Phase 3 confirmatory study – AHEAD 3-45 Phase 3 Program – ongoing ongoing • Eisai and ACTC started new Phase
Slide 11: Lecanemab – potential to lead the paradigm shift in the treatment of Alzheimer's disease
Lecanemab – potential to lead the paradigm shift in the treatment of Alzheimer’s disease Increased likelihood for Opportunity to be first with Opportunity to differentiate Further development lecanemab success full approval in US, Japan and programs EU Positive and consistent Accelerated approva
Slide 12: Financial Summary
Financial Summary 12 BioArctic AB
Slide 13: Net revenues and operating profit/loss Q1 2022
Net revenues and operating profit/loss Q1 2022 Net Revenues (MSEK) OPEX by item (MSEK) Operating Profit/Loss (MSEK) 11 60 48 45 8 43 40 42 42 7 38 7 7 40 32 -21 5 -30 -29 4 4 -34 20 -38 -37 -39 -44 0 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2020 2021 2022 2020 2021 202
Slide 14: Cash and net result Q1 2022
Cash and net result Q1 2022 Cash Balance (MSEK) Cash Flow From Operating Net Result (MSEK) Activities (MSEK) 1 050 1 036 1 000 960 930 892 848 801 -9 -13 -20 -21 -19 -27 -29 -29 -35 -37 -39 -40 -34 -38 -38 -44 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2020 2021 2022 202
Slide 15: Upcoming news and closing remarks
Upcoming news and closing remarks 15 BioArctic AB
Slide 16: Upcoming news flow
Upcoming news flow Alzheimer’s disease Parkinson’s disease Blood-brain barrier Other CNS disorders Lecanemab (Eisai) ABBV-0805 (AbbVie*) Brain Transporter (BT) Neurodegeneration • Rolling submission for accelerated • Data presented at technology platform • Data to be disclosed at approval in the US
Slide 17: BioArctic: With Patients in Mind
BioArctic: With Patients in Mind Great science Great projects Great partners Great people 17 BioArctic AB
Slide 18: Gunilla Osswald, CEO; Jan Mattsson, CFO; Oskar Bosson, VP Communications & IR
GUNILLA OSSWALD, CEO JAN MATTSSON, CFO OSKAR BOSSON, VP NEXT REPORT & IR COMMUNICATIONS & IR CONTACT • Next Report: Q1 Jan-Mar 2022 on April 28, 2022 • Contact: Oskar Bosson, VP Communications & IR +46 704 10 71 80 [email protected] To subscribe to financial reports/press releases and for more informa